Dec. 9, 2021
GREENVILLE, S.C. – Partner Christopher Hanson has joined the Board of Directors of SCBIO, a statewide, not-for-profit industry association and economic development organization formed to actively promote, build, support, expand, and convene South Carolina's life sciences industry. Nelson Mullins also is a member of the organization.
Hanson, based in Greenville, S.C. and Washington, D.C., leads the firm’s Food and Drug Administration (FDA) Regulatory Compliance & Litigation practice group. He assists clients with regulatory issues involving medical devices, human and animal drugs, in vitro diagnostics (IVDs), dietary supplements, cosmetics, radiation-emitting electronic products, and clinical laboratories. He has aided clients in consequential interactions with federal, state, and foreign regulatory agencies.
In his advisory practice, his work includes drafting FDA regulatory submissions as well as preparing public comments for agency rulemakings, guidance documents, advisory committees, and public policy venues. He provides strategic advice and regulatory due diligence to support corporate transactions and securities filings in the life sciences space. He also has experience counseling in FDA agency enforcement matters and conducting global internal investigations and audits.
SCBIO is the South Carolina affiliate of the U.S. Biotechnology Innovation Organization (BIO) and the exclusively dedicated advocate and 'voice' for the multifaceted S.C. life sciences industry, according to the organization. BIO champions biotechnology and its potential to provide better healthcare, enhanced agriculture, and a cleaner and safer environment for people around the world.
Established in 1897, Nelson Mullins is an Am Law 100 firm that has more than 850 attorneys and government relations professionals with offices in 11 states and Washington, DC. For more information on the firm, go to www.nelsonmullins.com.
These materials have been prepared for informational purposes only and are not legal advice. This information is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Internet subscribers and online readers should not act upon this information without seeking professional counsel.